Fig. 4.

DNA damage heterogeneity across BRCA-mutant primary breast cancers. (A) DNA damage signatures from MSigDB demonstrate a wide range of expression across all 941 primary breast cancers from The Cancer Genome Atlas, regardless of hormone receptor status or BRCA mutation status, highly correlated to (B) i. RAD51 gene expression regardless of ii. PAM50 subtype (green = normal breast; light blue = luminal A; dark blue = luminal B; pink = HER2-enriched; red = basal-like) or iii. BRCA1/2 mutational status (white = wild-type, 861 tumors, black = germ line (26 tumors) or somatic mutant [44 tumors]). (C) RAD51 gene expression significantly correlated with PARP inhibitor sensitivity signature regardless of BRCA status (R² = 0.6026; P = 4.11e–93) in the same 941 tumors.